Canada: Federal Court Finds PLAVIX Patent Invalid

Last Updated: January 17 2012
Article by Urszula Wojtyra

On December 6, 2011, Justice Boivin of the Federal Court held that Apotex infringed the patent that claims clopidrogel bisulfate (sanofi-aventis's PLAVIX) but that the patent was invalid: Apotex Inc. v. sanofi-aventis 2011 FC 1486, appeal pending.

The same patent ('777) had previously been the subject of litigation under the Patented Medicines (Notice of Compliance) Regulations. As reported in the November 2008 special edition of Rx IP Update, the Supreme Court of Canada upheld the Order of prohibition preventing the Minister of Health from issuing a Notice of Compliance ("NOC") to Apotex (2008 SCC 61). Following its loss in the Supreme Court, Apotex brought an impeachment action, and sanofi-aventis followed with an infringement action. The December 6 decision relates to both actions.

The '777 patent discloses and claims the enantiomer clopidogrel and its bisulfate salt, as well as processes for its manufacture. An earlier patent ('875) encompassed clopidogrel bisulfate within its claims and included an example describing the racemate. The claims also referred to enantiomers.

Starting with the position that the '777 patent is a selection patent, the Federal Court concluded that the invention of the '777 patent is a compound that is useful in inhibiting platelet aggregation, has greater therapeutic effect and less toxicity than the other compounds of the '875 genus patent, including the racemate and the opposite enantiomer, has the advantages of the salts (crystallize easily, not hygroscopic and sufficiently water-soluble) and the methods for obtaining that compound. Further, the Federal Court held that the patent made an explicit promise for the use of the compound in humans.

Invalidity. The Federal Court rejected Apotex's assertions that the '777 patent was invalid for overbreadth, insufficiency, lack of novelty and double-patenting. The Federal Court's decision is consistent with the Supreme Court's ruling on the latter two grounds.

The Federal Court found the patent invalid on the basis of lack of utility, both demonstrated or soundly predicted, and obviousness.

Demonstrated utility. Sanofi-aventis had argued that the promised utility had been demonstrated as of the Canadian filing date, at which time a phase 1 clinical study of the compound was underway. While some of the results of the double-blind study were known to sanofi-aventis at the date of filing, the study was not completed until one month later. The Federal Court held that the early results known by sanofi-aventis were inconclusive on the issue of the promised utility.

Sound prediction. With regards to sound prediction, the Federal Court found that sanofi-aventis had a "track record" studying compounds with similar structures to clopidogrel bisulfate. As a result of this "track record," sanofi-aventis established that it had a factual basis and sound line of reasoning for predicting that clopidogrel bisulfate could be used in humans. However, the Court found that the patent did not disclose this "track record," which the Court held was needed to assist the skilled person to predict the promised use. As a result, the patent failed the disclosure branch of the sound prediction test.

Obviousness. In contrast to the Supreme Court's finding that Apotex's allegation of obviousness was not justified in that proceeding, the Federal Court held the invention of the '777 patent "obvious to try." The Federal Court reasoned that the racemate of clopidogrel was part of the common general knowledge of the skilled person, that the skilled person would have been motivated to resolve the enantiomers of a racemate, and that a particular method of resolving the enantiomers would have been routine at the time.

Infringement. While in principle moot because of the finding of invalidity, the Federal Court nonetheless addressed sanofi-aventis's claim of infringement. The Federal Court held that Apotex infringed the '777 patent by, among other acts, importing clopidogrel bisulfate and exporting Apo-clopidogrel tablets to the United States.

In the U.S., the parties had entered into settlement agreements regarding the U.S. litigation relating to the U.S. patent claiming clopidogrel bisulfate. By the agreements, Apotex's liability for infringement in the U.S. was limited to 50% of its net sales. Apotex had argued that sanofi-aventis was precluded from recovering for the U.S. Apo-clopidogrel on the basis of these settlement agreements. The Federal Court disagreed, finding the agreements did not consider the '777 patent and were limited to the U.S. patent and U.S. litigation.

Sanofi-aventis's motion for an interim stay was dismissed. A number of generic manufacturers have since received NOCs for their clopidogrel bisulfate products.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions